Shots:

• AstraZeneca to receive $178M up front and up to $61M as sales-contingent payments while it continues to manufacture and supply Seroquel and Seroquel XR to Cheplapharm during a transition period. The transaction is expected to be closed in Q4’19
• The divestiture will allow AstraZeneca to focus on its main therapeutic areas by reducing its portfolio of mature medicines
• Seroquel & Seroquel XR are anti-psychotic therapies with antidepressant properties indicated to treat schizophrenia and bipolar disorder and has generated $47M & $61M revenue in 2018 in EU & Russia

Click here to­ read full press release/ article 

Ref: AstraZeneca | Image: AstraZeneca